Archemix Corporation Announces ARC1779 Data to Be Presented at Upcoming American Society of Hematology Annual Meeting, December 6-9, 2008

Published: Dec 04, 2008

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, today announced that data from the company’s Phase 2a clinical trial of ARC1779 will be presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco, Calif., December 6 to 9, 2008.

Back to news